Читать книгу Interventional Cardiology - Группа авторов - Страница 327

On the basis of the Organization for the Assessment of Strategies for Ischemic Syndromes (OASIS 6) trial [93], which assessed the efficacy of fondaparinux in STEMI patients (treated with and without primary PCI) and which showed that there were higher rates of periprocedural complications in the PCI arm, due principally to guiding catheter thrombus, fondaparinux is not recommend as a sole anticoagulant for primary PCI [3,4].